Gilead Secures Safety Advantage For TAF In HBV, Keeps Edge In HCV
This article was originally published in The Pink Sheet Daily
Top-line Phase III trials support transition plan from Viread. In hepatitis C, Gilead may be further strengthening its lead with a priority review for a pan-genotypic combo pill that replaces Harvoni's ledipasvir with a more potent NS5A inhibitor.
You may also be interested in...
Licensing agreements and bolt-on acquisitions to strengthen its R&D pipeline are still in Bayer’s sights as the COVID-19 pandemic and currency devaluations have led to the need for job cuts and substantial cost savings at the big pharma company.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Twenty-seven guidance documents have been posted on the tracker since its last update.
Despite a recent disappointment in a similar partnership with BioNTech, Genentech is pushing ahead with its neoantigen-targeting strategy.